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Purpose. We retrospectively evaluated it with Elekta Synergy VMAT and a patented system to achieve high quality fusion image
and immobilization.
Methods. The procedure improved thermoplastic immobilization by means of a sub-mask (eXaSkin by Anatomical-Geometry). A
similar number of CT and axial magnetic resonance images were acquired with the same immobilization. It is possible using
eXaFrame system. The treatment was designed with the inverse module for VMAT of Pinnacle v.9.2 (SmartArc), with multiple arcs
performed with Elekta Synergy. The dose scheme employed is the Lagerwaard one: [WBRT (20Gy) +SIBmts (40Gy)]/5 frac . Daily
patient positioning was checked with IGRT (Elekta XVI). First step is WBRT: two arcs VMAT CCW (178–60◦ and 300–182◦) with the
following objectives: brain (Dmax=21Gy, weigh=100 and Dmin=20Gy, weigh=50), eyes (Dmax=10Gy, weigh=1). Later on, we
focused on metastases separately: we block the optimization prophylaxis (Optimization Type None) and create three structures:
VI1 =PTV (mts1) + 5mm, VI2=PTV (mts2) + 5mm, Epx=encéfalo-VI1-VI2. The objectives were: PTVi (Dmax=44Gy, weigh=100
and Dmin=40Gy weigh=50), Epx (Dmax=30Gy) and brain stem (Dmax=23Gy). Treatment veriﬁcation was performed with the
Compass-Matrixx system.
Results. Until now we have treated 11 patients, being the differences in fusion images less than 1mm and mean IGRT correction
of 1.24mm. No acute toxicity and hair problems. Of the 11 patients treated 7 are alive without brain progression or neurological
toxicities, 3 died after systemic progression of the disease and 1 of them because of complications associated with systemic
treatment. Total time spent on the process, including contouring, treatment design and veriﬁcation, without considering the
learning curve, is about 7h.
Conclusions. Hypofractionated stereotactic radiotherapy with eXaFrame and eXaSkin in patients with up to three brain metas-
tases with IGRT and VMAT is a workable solution. It’s a rapid and accurate technique that has a higher conformity index than
conventional summation of WBRT and radiosurgery boost.
http://dx.doi.org/10.1016/j.rpor.2013.03.561
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Introduction. The swannomas are benign tumors of neural tissue that can be treated with surgery, radiosurgery or FSRT.
Objective. Analyze the results of auditory toxicity and treatment complications of vestibular schwannomas at our institution.
Materials and methods. Between 2004 and 2011, 95 patients have been evaluated for treatment with FSRT, with a median age of
57 years. Tumor size was less than 1 cm in 14.7% of patients, between 1 and 1.99 cm in 35.8%, between 2 and 2.99 cm in 33.7%,
between 3 and 3.99 cm in 9.5% and greater than 4 cm in 6.3%. The hearing before treatment was normal in 4.2%, with loss of
less than 30dB in 52.6%, greater than 30dB loss in 25.3% and deafness in 17.9%. 80.9% of patients had not undergone surgery,
while 14.9% they were been intervened once and 4.3% twice. Balance remained intact in 63.2% of patients with mild disease in
25.3% and severe in 11.6%. Matthies classiﬁcation: 23.2% of patients were T1, 26.1% T2, 31.9% T3 and 18.8% T4. The treatment
has been performed in 72 of the 95 patients evaluated, excluding those who lacked the teeth necessary for inmovilization with
the Gill–Thomas–Cossman’s guide. The therapy has been performed with cone in 83.3% of patients and with multileaf in 16.7%.
The median dose was 54.78Gy with a median treatment duration of 42 days.
Results. Hearing after FSRT remained unchanged in 81.9% of patients, improved in 4.2% and worsened in 13.9%. Most patients
had no complications (95.8%), with edema of trunk in 1 patient and radiation necrosis in 2 patients. Complications ocurred in
patients who had previously been operated.
Conclusion. FSRT is an effective treatment in vestibular swannomas with hearing preservation greater than surgery, and with low
complication rate.
http://dx.doi.org/10.1016/j.rpor.2013.03.562
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Introduction. Trigeminal neuralgia (TN) incidence is 4.5/100,000 and is highly disabling. Most cause of the classical (idiopathic
or essential) is vascular. 30 years ago a Spanish center performed the ﬁrst treatment of TN (Dr Larrea). The SRS is used when
medication or other methods are not effective. SRS is also used in patients with medical co-morbidities.
Objectives. Demand arising in our center led to commissioning and ﬁrst 5 pilot cases at Meixoeiro (CHUVigo) as described below.
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Methods. Modeling cones 5–7.5mm (BrainLab®); establishing protocol; treatment simulation phantom. We prepared commission-
ing and subsequently invited a national expert to perform pilot cases and treatment 5 patients.
Results. Accuracy<0.4mm. Protocol: subaracnoid lumbar infusion of 10ml of contrast. Trendelemburg ten minutes with his head
tilted to the affected side. CT slices of 0.625. Image transfering-Contouring.PTV 2–3mm after the exit of the brain stem. PTV
3–4mm to the Gasserian ganglion-Prescription 65Gy to ≥95% isodose; tangential > 30Gy -accuracy=0.3–0.5mm. Cones 5–7.5mm
-brain stem: D0.1 cm3 <15Gy D0.01 cm3 <30Gy, Dmax<35Gy. Healthy brain D 5cm3 <12Gy. Arc angles > 45◦. Homogeneity and
conformation index= standard. 5 patients were treated: 3 essentials and 2 symptomatics. 1 surgery twice. 1 irradiated by TN
twice. Parameters 4 patients (excluding 1 with previous SRS): average/median: -PTV coverage isodose 90%/90%; D90 100%/100%;
Dmax (Gy) 79.2/77.91; Dmed 75.25/74.55; -brainstem: Dmax 33.72/30.95, Dmin 0.42/0.29; Dmed 1.81/1.81;V12Gy brain stem (cm3)
0.14/0.13-Dist PTV Bstem (mm) 2.27/2.50-mmCollimator 6/6-Vol PTV (cm3) 0.02/0.01- healthy brain V12Gy (cm3) 1.27/1.22. -
Response 50% (2/4), latency 2–6 weeks. Excluding 2 sintomatic, response was 66.66% reducing medication 30% (1 case). 1 patient
worsens within 2 week. One patient died of other cause.
Conclusions. The SRS is a safe and effective method in the treatment of neuralgia. Possible from linear accelerator, with stringent
controls because it requires greater accuracy. Results of the literature support a great success of the SRS in TN.
http://dx.doi.org/10.1016/j.rpor.2013.03.563
